

2021 Annual Results Presentation

March 2022

GENOR
BIOPHARMA



Disclaimer

By receiving this document or attending the meetings at which this document is presented, you agree to be bound by the following restrictions:

This document is provided to you solely for your exclusive use and information and is not for public dissemination. The information contained in this document has not been independently verified. No representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, reliability or correctness of any information or opinions contained herein. The information contained in these materials should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated or revised to reflect developments which may occur after the date of which information is given in this document. Any party receiving this document will rely solely upon its own independent examination and assessment and any information contained herein. None of the Company, nor any of its respective affiliates, directors, supervisors, officers, employees, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of or reliance on this document or its contents or otherwise arising in connection with this document.

The information contained in this document includes historical information about, and relevant to, the Company that should not be regarded as an indication of the future performance or results of the Company, or an indication that there has been no change in the information about and relevant to the Company since the date hereof or since the dates as of which information is given in this document. This document contains forward-looking statements. The forward-looking statements herein are based on the Company's beliefs and expectations about the future and on a number of assumptions about the conditions of general economy, global and local market and specific industry and the Company's operations. The forward-looking statements are subject to a number of known and unknown factors, including factors beyond the Company's control, which may cause the Company's actual results or performance to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are not a guarantee of future performance. Accordingly, you should not place undue reliance on such forward-looking statements. The Company, and respective directors, supervisors, senior officers, employees, affiliates, advisers and representatives have no obligation and do not undertake to update or otherwise revise such opinions or forward-looking statements for events or circumstances that occur after the date hereof. Certain factual or predictive statements in the document are derived from external sources and have not been independently verified by the Company or any of its respective directors, supervisors, senior officers, employees, affiliates, advisers or representatives.

This document or any information contained in it does not constitute or form part of, and should not be construed as, any offer for sale or invitation, or solicitation of an offer, to subscribe for or purchase any securities of the Company in the United States, Hong Kong or anywhere else. No part of this document, nor the fact of its distribution, shall form the basis of, or be relied upon in connection with, any decision, contract, commitment or action whatsoever, with respect to any proposed investment or transaction or otherwise.

This document contains no information or material which may result in it being deemed (i) to be a prospectus within the meaning of section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (ii) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong and is subject to material change without notice.

By accepting delivery of the information contained herein, you are agreeing (i) that you have read, understood and agree to comply with the contents of this notice and disclaimer, and (ii) you will maintain absolute confidentiality regarding the information disclosed in this document. If you do not accept these conditions and give the acknowledgements and representations set out above, please immediately return this document. The information contained herein may not be copied, reproduced, redistributed or otherwise disclosed, in whole or in part, to any one person (whether within or outside your organization/firm), in any manner or published, or refer to it publicly, in whole or in part, for any purpose. The distribution of this document in certain jurisdictions may be restricted by law and, accordingly, by accepting delivery of the information contained herein, you represent that you are able to receive this document without contravention of any unfulfilled registration requirements or other legal restrictions in the jurisdiction in which you reside or conduct business.

Agenda






01

Business Review

Vision – Global Innovative Biotech Company

- Adjusted the priorities of original product pipelines
- Focus on the product pipelines with higher added values
- Create more innovative products with higher values



- Established FIC / BIC potential drug discovery platform focusing on IO bi/multi-specific antibodies
- World-renowned experts in oncology and immuno-oncology joined our Scientific Advisory Board



Discovery and
Research



CMC



Clinical
Development



Commercial-
ization




Business
Development

Fully-integrated, end-to-end biological platform encompasses all the key biologic drug development functionalities



Business Highlights from 2021



(1) PCC: Pre-clinical Candidate



Key Milestones in Late-stage Pipeline from 2021

1 NDA approval, 1NDA under technical review and advancing 2 Ph3 clinical trials

Product	Description	Trials / Indication	Commercial Rights	Stage	Key Milestones
GB491 Lerociclib	a novel, potent, selective oral bioavailable CDK4/6 inhibitor co-developed by the Company and G1 Therapeutics	CDK4/6+AI (combo w/ letrozole): 1L HR+/HER2- BC ⁽¹⁾	APAC ex-JP	Phase 3	FPD ⁽²⁾
		CDK4/6+SERD (combo w/ fulvestrant): 2L HR+/HER2- BC		Phase 3	FPD
GB242 Jiayoujian 佳佑健®	Infliximab, biosimilar to Remicade (TNF- α)	RA, AS, Ps, CD, UC ⁽³⁾	Worldwide	NDA ⁽⁴⁾ Approved	NDA Approved
GB226 Geptanolimab, Aibining 艾比宁®	a novel PD-1 mAb drug candidate	Pivotal: r/r PTCL ⁽⁵⁾	China	NDA under technical review	NDA under technical review

(1) BC: Breast Cancer

(3) RA,AS,Ps,CD,UC: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and Pediatric Crohn's Disease and Fistulising Crohn's Disease

(5) r/r PTCL: relapsed and refractory peripheral T-cell lymphoma

(2) FPD: First Patient Dosed

(4) NDA: New Drug Application



Commercial Operation and Manufacturing for Late-stage Pipeline

Commercial Operation Foundation

Hybrid model for product commercialization

- **Core market:** Small, capable, well-rounded commercial team of our own for core market to manage branding, market access, pricing, channels and supply chain
- **Non-core market:** Collaboration with CSO of high quality

Market warming up

- Covered over 70% doctors in lymphoma by daily bases as well as other Oncologist e.g. GYN
- Participated domestic or regional hematology or lymphoma conferences
- Held presentations with GB226 PTCL study data
- Covered over 350 core hospitals and a wide range of experts offline and online
- Received greater and higher expectations from doctors and patients for the launch of GB226

Yuxi Commercial Manufacturing Site



Clinical and commercial supply

- Supply drugs in Ph3 clinical trial and commercial manufacturing of our product like PD-1


Advanced Technology

- Concentrated fed-batch (CFB) and continuous perfusion technologies
- Bioreactors: 3x200L, 4x500L
- Higher cost efficiency
- Industry leading yield



Key Milestones in Early-clinical-stage Pipeline from 2021

Product	Description	Trials / Indication	Commercial Rights	1Q	2Q	3Q	4Q	1Q22	
GB492	a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226	Solid Tumors	APAC ex-JP	Ph1 IND Mono or Combo		Ph1/2a 400µg group FPD finished			
GB261	CD20/CD3, bi-specific antibody	NHL	Worldwide	FIH AUS CTA Submission		FIH FPD			
GB263T	EGFR/cMET/cMET, tri-specific antibody	NSCLC	Worldwide					FIH AUS EC Approved	CN IND Accepted



- Differentiated design
- Fast execution with cross-function cooperation, could finish all IND-enabling work in 12 months
- Experienced in-house CMC, made these hard-to-develop candidates into clinical drugs with high productivity and quality
- Science-based clinical development plans and strategic regulatory pathway design



New Discovery-stage Pipeline from 2021: Focusing on IO FIC/BIC Potential Antibodies While Exploring Cutting-edge Technology

Discovery-stage pipeline in 2021

pipeline		Indications	Lead discovery
Bi/multi-specific antibody / fusion protein	GBD201	NSCLC, ESCC, other solid tumors	
	GBD202	NSCLC, GC, other solid tumors	★
	GBD209	NSCLC, pancreatic cancer, other solid tumors	
	GBD211	NSCLC, HCC, other solid tumors	
	GBD212	NSCLC, HNSCC, other solid tumors	
	GBD208	NSCLC, pancreatic cancer, other solid tumors	
	GBD204	SCLC and other solid tumors	
mRNA	GBD401	Solid tumors	

Novel discovery from 2022

FIC / BIC potential

- Comprehensive assessment before entering into next stage.
- Advance only FIC/BIC potential candidates

IO Focus

- Immune Check Point Inhibitor
- T-Cell Engager for solid tumour
- Cytokines Drug Conjugates

The first one in PCC

- By showing outstanding results in mouse tumor model, the FIC potential candidate **GBD202** has entered into PCC stage in 2022

IND

- E: 1 IND per year from 2023


*mRNA anti-cancer drug discovery collaboration : signed term sheet in Mar 2022




FIC/BIC Potential Drug Design Strategy and Integrated Development Platform

FIC/BIC Potential Drug Design Strategy

1. Focus on frontier IO targets
2. Various mechanism and targets to co-regulate the core pathways of the immune network
3. Specifically target to tumor microenvironment regulatory immune cells




FIC/BIC Potential Drug Design Platform





Scientific Advisory Board, Accelerating Global Innovation



**Dr. Zhijian
CHEN**

**Professor at
the University
of Texas
Southwestern
Medical Center**

- investigator at the Howard Hughes Medical Institute
- elected to the National Academy of Sciences
- Breakthrough Prize in Life Sciences



**Dr. David
Kerr**

**Professor of
Cancer
Medicine at
the
University of
Oxford**


- former President of the European Society of Oncology (ESMO)
- fellow of the British Academy of Medical Sciences
- Harvard Medal of Global Health: Distinguished Leadership Award



**Dr. Alex
A. Adjei**

**Professor of
Oncology and
Pharmacology
at the Mayo
Clinic**

- Leader of the Thoracic Oncology Program and Head of Mayo Clinic's Early Cancer Therapeutics Program
- member of the National Cancer Institute's Board of Scientific Counsellors



**Dr. Leonard
Saltz**

**Professor,
Weill
Cornell
Medical**

- Executive Director for Clinical Value & Sustainability
- One of the leading physicians in colorectal cancers in the United States



**Dr. John R.
Zalcberg OAM**

**Professor of
Medicine at
Monash
University**

- Co-Chair of the Cancer Drugs Alliance and immediate past Chair of the Australian Clinical Trials Alliance
- Medal of the Order of Australia Award
- Cancer Achievement Award



**Dr. John F.
Seymour**

**Professor at the
Peter MacCallum
Cancer Centre &
Royal Melbourne
Hospital**

- Director of the Department of Hematology of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital
- co-chair of the federal ministerial Blood Cancer Taskforce



**Dr. Yangxin
FU**

**Professor at
Tsinghua
University**

- an internationally renowned cancer immunologist
- has pioneered novel immunotherapeutic approaches against cancer including methods to potentiate conventional cancer treatments.



Seasoned Management Team with Proven Track Records



Dr. Feng GUO

Chairman of the Board, CEO



Dr. Shuhua HAN

Chief Scientific Officer, CSO



Dr. Joe ZHOU

President



Ms. Tong LI

Chief Medical Officer, CMO



Mr. Wende CHEN

Chief Operation Officer, COO



Mr. Qibin Liang

Chief Technology Officer, CTO




Mr. Mark F. KUBIK

Chief Business Officer, CBO




Ms. Yao CHEN

Head of Regulatory Affairs





End-to-end Integrated Platform



The background of the slide is an abstract, artistic rendering. It features a deep blue, rippling surface that resembles water. Scattered throughout are numerous translucent, glowing blue bubbles of various sizes. Several large, dark red, textured shapes, which look like coral or biological growths, are positioned at different points. A prominent one in the lower-left foreground has a long, thin, translucent appendage extending downwards. The overall lighting is cool and ethereal, with a white curved shape on the right side of the frame.

02

Pipeline Introduction





A Robust Pipeline- Development Stage Assets Focusing on Global Opportunities

Product	Target/MoA (reference drug)	Indication	Classification	Commercial Rights	Discovery	Pre – Clinical	IND	Phase 1	Phase 2	Pivotal	NDA
GB491	CDK4/6+AI (combo w/ letrozole)	1L HR+/HER2- BC	Novel (In-license)	APAC ex-JP ⁽¹⁾							
	CDK4/6+SERD (combo w/ fulvestrant)	2L HR+/HER2- BC									
	CDK4/6+ EGFR (combo w/ osimertinib)	EGFR-Mutant NSCLC									
GB242	TNF- α (infliximab)	RA, AS, Ps, CD, UC	Biosimilar (In-house)	Worldwid							NDA Approved
GB226	PD-1	r/r PTCL	Novel (In-license)	China							NDA under priority review
		2L+ Cervical Cancer									
		ASPS									
		r/r PMBCL									
	PD-1+VEGFR (combo w/ fruquintinib)	2L/3L+ EGFR+ NSCLC 2L+ mCRC									
GB492	PD-1 (combo w/ GB226*)+STING	Solid Tumours	Novel (In-license)	APAC ex-JP ⁽²⁾							
GB221	HER2	HER2+ 1L/2L+ mBC	Novel (In-house)	Worldwide							
GB223	RANKL	GCTB, PMO	Novel (Co-develop)	Worldwide							
GB241	CD20 (rituximab)	1L DLBCL	Biosimilar (In-house)	Co-development							
GB224	IL-6	Inflammatory Disease	Novel (In-license)	China							
GB251	HER2 ADC	HER2+ 1L/2L+ mBC	Novel (Co-develop)	Worldwide							
GB261	CD20 $\times$ CD3	NHL	Novel (In-house)	Worldwide							
GB262	PD-L1 $\times$ CD55	Cancers	Novel (In-house)	Worldwide							
GB263T	EGFR $\times$ c-Met $\times$ c-Met	NSCLC	Novel (In-house)	Worldwide							
GB264	Claudin 18.2 $\times$ CD3	GI Cancers	Novel (In-house)	Worldwide							
GB265	PD-L1 $\times$ TIGIT	Cancers	Novel (In-house)	Worldwide							
GB266	PD-L1 $\times$ L.AG3 $\times$ LAG3	Cancers	Novel (In-house)	Worldwide							
GB267	Undisclosed	Cancers	Novel (In-house)	Worldwide							
***	Undisclosed	Cancers	Novel (In-house)	Worldwide							

Notes: (1) Clinical trials are sponsored by G1 Therapeutics. (2) Clinical trial is sponsored by ImmuneSensor Therapeutics; * four undisclosed candidates in discovery stage



Portfolio Strategy Centered Around the Cancer-Immunity Cycle





GB491 (Lerociclib) – Well-positioned to Capture the Huge Breast Cancer (eBC & mBC) and HNSCC Markets in APAC


FPD for 2L HR+/HER2- BC Ph3 trial in Oct 2021, FPD for 1L HR+/HER2- BC Ph3 trial in Jan 2022

■ We hold development and commercial rights in APAC excluding Japan


■ We are the second domestic company to obtain the IND approval for phase 3 clinical trial for CDK4/6 inhibitor.

≥1.5x Opportunities in APAC* vs. in China only


Ibrance Sales



Herceptin Sales



Verzenio (Eli Lilly)'s successful MONARCH-E study in adjuvant setting eBC



- **Continuous dosing** contributed to the success of MONARCH-E compared with intermittent therapy in PALLAS study
- **Different** relative effects on CDK4/6
- **Fewer drug discontinuations** in MONARCH-E compared with PALLAS (16.6% vs 42.2%)

Company	Drug	China Status	Setting	Registry / Approval Date	Patent Expiry
Pfizer	Ibrance	Launched	1L	Aug-18	Jan-23
Eli Lilly	Verzenio	Launched	1L	Dec-20	Nov-29
Hengrui	SHR6390	Launched	2L	Dec-21	
Novartis	Kisqali	NDA Submission	1L	Oct-21	Aug-29
Hengrui	SHR6390	Phase 3	1L	Oct-19	
Genor	Lerociclib	Phase 3	1L / 2L+	Jul-21	
Sihuan	XZP-3287	Phase 3	2L	Aug-21	
Sihuan	XZP-3287	Phase 3	1L	Dec-21	
Fosun	FCN-437	Phase 3	1L / 2L+	Sep-21	
BeBetter	BEBT-209	Phase 3	2L+	Dec-21	
Sino Biopharma	TQB3616	Phase 3	2L	Dec-21	
Sino Biopharma	TQB3616	Phase 2	1L	Feb-21	
Beta	BPI-1178	Phase 1/2a	1L	Nov-19	
BeBetter	BEBT-209	Phase 1b	1L	Nov-20	
Betta	BPI-16350	Phase 1	-	Jun-18	

Source: G1 Therapeutics, FDA, ESMO 2020, PubMed, CIC

* RMB1.7bn market is calculated based on roughly 100k HNSCC patients in China in 2030, 70% are HPV-unrelated, 20% penetration rate of CDK4/6 drugs, and roughly RMB120k annual price

2 Potential extension to 2028; * 2018 APAC Sales Data excluded Japan and Australia



GB491 (Lerociclib) – Potentially Best-in-Class CDK4/6 Inhibitor

Superior Efficacy Profile & Better Tolerability

Higher ORR vs. Palbociclib in Paloma-3 Trial

	Lerociclib Phase 1/2a (ongoing) ¹	Eli Lilly Monarch-2	Pfizer Paloma-3	Novartis Monaleesa-3
Line setting	Median 2L+	1/2L	1L+ (2L 40%, 3L 25%)	1/2L
Treatment	Lerociclib + fulvestrant	Abemaciclib + fulvestrant	Palbociclib + fulvestrant	Ribociclib + fulvestrant
ORR	31.6%	48.1% vs. 21.3%	24.6% vs. 10.9%	32.4% vs. 21.5%
CR	0	3.5% vs. 0	NA	1.7% vs. 0
PR	31.6%	44.7% vs. 21.3%	NA	30.8% vs. 21.5%
SD	47.4%	34.3% vs. 51.2%	NA	33.3% vs. 34.3%
DCR ²	79.0%	82.4% vs. 72.6%	NA	65.7% vs. 55.8%
mPFS	28.6 mo	16.4 vs. 9.3 mo	9.5 vs. 4.6 mo	20.5 vs. 12.8 mo

Longer treatment duration requires therapeutics with better tolerability



Potentially best safety profile across the CDK4/6 drug class


	Lerociclib ¹	Abemaciclib	Palbociclib	Ribociclib
Trial	NCT02983071	MONARCH-2	PALOMA-3	MONALEESA-3
Phase	I/IIa	III	III	III
Line setting	Median 2L+	1/2L	1L+ (2L 40%, 3L 25%)	1/2L
Treatment	Lerociclib + fulvestrant	Abemaciclib + fulvestrant	Palbociclib + fulvestrant	Ribociclib + fulvestrant
AE (%)	All Gr3/4	All Gr3/4	All Gr3/4	All Gr3/4
Neutropenia	55% 35%	46% 27%	79% 62%	70% 53%
Leukopenia	40% 15%	28% 9%	46% 25%	28% 14%
Nausea	15% 0%	45% 3%	29% 0%	45% 1%
Diarrhea	25% 0%	86% 13%	19% 0%	29% 1%

Source: G1 Therapeutics; CIC; ESMO 2020; Bisi J. E., Sorrentino J. A., et al; Oncotarget. 2017; 8: 42343-42358; Ping Chen, Nathan V. Lee, et al; Mol Cancer Therapeutics. October 1 2016 (15) (10) 2273-2281; DOI: 10.1158/1535-7163.MCT-16-0300; Dickler et al, Clin Cancer Res; 2017; Notes: ¹ 150mg BID group; ² DCR=CR+PR+SD.

Source: G1 Therapeutics, FDA, ESMO 2020 poster; data cutoff: 17 Apr 2020
Note ¹: for 150mg BID dosing group



GB491 – Advancing Phase 3 Clinical trials



Clinical and Regulatory Progress in 2021:

- Completed all the activities required for Ph3 IND in **12 months**
- 2L Study: **Waived Phase 1b bridging study**, *NDA is expected to be advanced for 1 year.*
- 1L Study: **Safety lead-in study** shorten the trial time for half year.
- Wider range of patients, optimized sample size and mid-term analysis cut-off.** *The full analysis is expected to be advanced for 1 year.*

CMC Achievements

- Cooperated with 4 CDMOs in China, Europe and the United States.** *Solved technology, communication, laws and regulations problems in various countries(regions).*
- Produced APIs, clinical trial drug and placebo supply within one year.** *Guaranteed the high advancement of the project.*



Other key Late Stage Candidates GB242 and GB226

Introduction

GB242 – Infliximab biosimilar

- Biosimilar product candidate to Infliximab.
- Indications: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriasis (PsO), Crohn's Disease (CD), pediatric Crohn's Disease (pCD) and Ulcerative Colitis (UC).

GB226 – PD-1

- Humanized, IgG4 mAb targeting the PD-1 receptor on immune cells.
- Selectively blocks dual ligands (PD-L1 and PD-L2), and restores the ability of the immune system to recognize and kill tumor cells.

Latest Progress

- NDA approval in Feb 2022



- NDA for r/r PTCL is under technical review

Abbreviations: RA=Rheumatoid Arthritis, AS=Ankylosing spondylitis, Ps=Psoriasis, CD=Crohn's disease; UC=Ulcerative Colitis


Source: Evaluate pharma, annual reports, CDE, China Insights Consultancy, public filings; *Aggregate sales for Yisaipu, Remicade, Humira and Enbrel; **CFDA/NMPA approval



GB492 – A Potentially First-in-class STING Agonist in China

Ph1/2 FPD in Sep 2021

Mechanism of Action



- STING is the major mediator of innate immune sensing of cancerous cells
- STING agonists can activate the cGAS-STING signaling and significantly enhance the efficacy of cancer immunity cycle when using in combo with other immune checkpoint inhibitors (ICI)
- Multiple studies show that STING agonist may be used as a new immune stimulatory therapy

STING agonist, as an immune stimulatory therapy, may further increase the response of immune checkpoint inhibitors for patients

Merck's trial demonstrated **robust efficacy of PD-1 + STING combination therapy** comparing to single agent


- Preliminary data from Merck's Phase 1 clinical trial for a STING agonist as monotherapy and in combination with Keytruda, in patients with advanced solid tumors or lymphomas
 - The **combination arm had partial responses of 43%** (three out of the seven patients) in HNSCC
 - By contrast, **Keytruda monotherapy showed ORR of 18%** in KEYNOTE 012 trial in platinum-refractory HNSCC

GB492 in combo with GB226 (PD-1) is potentially the **first-in-class therapy in China**

- ImmuneSensor Therapeutics, our licensor, is currently conducting a Phase 1/2 trial for STING alone or in combo with ICI in the US for solid tumors
- We **plan to develop GB492 in combination with GB226 as a first-in-class therapy** for solid tumors in China




GB492 – Advancing Clinical Development



Progress achieved in 2021:

- **IND Approval** for an innovative FIH trial Design combining 2 dose escalation in one study
 - GB492 mono
 - GB492 + PD-1 combo
- GB492 Mono Initial clinical data: 400 µg Chinese pts safety well tolerated, comparable to US safety data
- **Waive Mono Escalation** in China and directly start 800 µg GB492 + GB226 (PD-1) combo escalation , thus advance 3-6 months than regular method

Clinical Development Strategy






GB261 – A Highly Differentiated CD20/CD3 BsAb for B-cell Lymphoma

FIH FPD in AUS in Oct 2021

The first T-cell engager with super low CD3 binding affinity and maintaining Fc effector functions (ADCC and CDC) , rendering better safety and multiple mechanisms to better kill cancer cells.



CDR grafting and backmutation





GB261 Significantly Inhibits Rituximab-resistant Tumor Growth (in vivo)


GB261 induces more Rituxan-resistant Raji cell killing in PMBC-engrafted B-NDG mice than REGN1979 analog.





GB261 Induces T cell Activation with Less Cytokine Releases

GB261 stimulates less cytokine release compared to that of REGN1979 analog.






GB261 Clinical Data Conforms to MOA and Pre-clinical Discovery

Preliminarily showed better safety at 20-200 times of starting dose

Drug Candidate	GB261	Mosunetuzumab (RG7828)	Odronextamab (REGN1979)	Glofitamab (RG6026)
Starting Dose	1mg	50µg	30 µg	5 µg

PK and cytokine data from 1mg dosed group conforms to MOA and pre-clinical discovery



Drug accumulation observed in IV dosing of 1 mg QW; Drug trough concentration has not reached steady state after 4 weeks of dosing


- The terminal half-life of GB261 is estimated to be around 1 week or more
- Based on preclinical data, clinical efficacy may be observed at 10-30mg, and more robust clinical efficacy is expected at 100-300mg

No cytokine release observed in 1mg group

- Based on preclinical data, cytokine release may occur in the 3-10 mg dosing group



GB261 – Advancing Clinical Development



Clinical and Regulatory Progress in 2021:

- **Optimized Dose Escalation and Expansion in Ph1 trial.**
 - Starting dose from 1mg
 - Accelerated titration + standard titration
 - Less undertreated patient number
 - Speed up to effective dose range
 - Close monitoring and careful management of safety
- Initial clinical data at 1mg revealed PK and safety, no CRS

CMC Achievements

- **Within 12 months**, completing the process from sequence determination to global multi-center clinical drug delivery
- **Expression level of 5-6g/L and purity of 99.5%**

Clinical Development Plan:

Fast to Market Strategy (Preliminary)

Single-Arm Trials in CN/US/AUS

R/R FL

R/R DLBCL

R/R MCL

Large Indication Strategy

1L DLBCL & Other Indications

GB261 + PD-1 + SOC

GB261 + SOC




GB263T – the First EGFR/cMET/cMET Tri-specific Antibody for NSCLC

Global rights, global innovation, blockbuster potential

In comparison with JNJ-61186372, GB263T is differentiated in design

GB263T



Multiple MOAs


- Inhibit EGFR/c-MET relevant signaling
- Mediate receptor endocytosis
- ADCC
- 2 : 2, asymmetric structure
- Binding to two “c-Met” with different epitopes
- IgG1, ADCC enhanced through AAs mutation

JNJ-61186372 (Amivantamab)



- 1 : 1, asymmetric structure
- Binding to one “c-Met”
- IgG1, ADCC enhanced through high afucosylation

GB263T inhibits activity of cells with EGFR ex20ins mutations




GB263T showed a dose-dependent inhibition of the viability of cells containing 3 different EGFR exon 20 insertion mutations (including D770del-insGY, D770-N771 insSVD, and H773-V774 insH)

GB263T induces tumor killing in EGFR mutations CDX models


EGFR Ex20ins (D770Del/InsGY)

Ba/F3 D770Del/InsGY xenograft



EGFR Ex19del/T790M/C797S

Ba/F3 ex19del/T790M/C797S




GB263T inhibits tumor growth in EGFR ex20ins models with three different mutations: EGFR D770Del/InsGY, EGFR D770_D770_N771insSVD, and EGFR Ex19del/T790M/C797S



GB263T – Advancing FIH IND and Clinical Trials

EC approved for FIH AUS clinical trial and China IND submission accepted by NMPA in Mar 2022



Cross-Department Cooperation

- **Cooperated with world famous PI** to design clinical trial
- Finalized the clinical trial scheme within one day while the Tox data readout
- From CMC initiation to FIH submission in Australia **within 12 months**. Better than industry average
- **Expression level of 5-6g/L and purity of 99.5%**

Clinical Development Plan





03

Upcoming Events

GENOR
BIOPHARMA



Upcoming Milestones

Key Events	Timing
GB242 (TNF- α) – Commercial Launch	2022
GB226 (PD-1) – NDA approval for 2L r/r PTCL	2022
GB492 (STING) – FPD combined with GB226	2H2022
GB261 (CD20/CD3) – IND approval in China	2H2022
GB261 (CD20/CD3) – Initial POC readout	2H2022
GB263T (EGFR/cMet/cMet) – IND approval in China	2H2022
GB263T (EGFR/cMet/cMet) – FPD in Australia	2H2022
GB491 (CDK4/6) – NDA for 1L/2L HR+/HER2- mBC	2L: 2023 / 1L: 2024
GB492 (STING) – Initial POC readout combined with GB226	2023
GB263T (EGFR/cMet/cMet) – Initial POC readout	2023
GB267– Clinical application / IND in Australia and China	2023
Achieve mRNA anti-cancer drug discovery collaboration	2H2022
1 FIC / BIC potential drug candidate entering IND enabling stage	From 2022
1 IND for FIC / BIC potential candidate every year	From 2023

The background of the slide is a deep blue field filled with a complex network of glowing blue and yellow lines, resembling a neural network or a molecular structure. Several bright yellow-orange points of light are scattered throughout, some appearing as nodes or synapses. The overall effect is one of high-tech, scientific, or biological complexity.

04

Financial Overview



Financial Overview – Income Statement

RMB' mn	Year Ended 31 December	
	2021	2020
Revenue	-	10.3
Cost of revenue	-	(2.6)
Gross profit	-	7.7
Selling expenses	(98.6)	-
Administration expenses	(207.4)	(241.4)
Research and development expenses	(612.7)	(696.6)
Other income-net	44.8	(4.4)
Other gains/(losses)-net	14.8	(1,968.3)
Operating loss	(859.1)	(2,903.0)
Finance income	23.7	3.7
Finance costs	(30.9)	(137.0)
Finance costs-net	(7.2)	(133.3)
Loss before income tax	(866.3)	(3,036.3)
Income tax credit	0.9	5.8
Loss for the year	(865.4)	(3,030.5)

Expenses

- R&D expenses decreased, mainly due to the decrease of employee share-based payment expenses.
- The decrease in administration expenses was mainly due to the decrease of listing expenses.
- The selling expenses was due to the set up of commercial team.

Net loss for the year

- Net loss for the year was RMB 865.4mn.

* All numbers are rounded to one decimal place



Financial Overview – Balance Sheet

RMB' mn	Dec-21	Dec-20
Cash and cash equivalents	2,200.6	2,929.7
Restricted bank deposits	2.0	2.0
Inventories	49.7	31.5
Contract cost	1.8	1.8
Other receivables, deposits and prepayments	132.5	108.7
Amounts due from related parties	0.0	27.7
Total Current Assets	2,386.6	3,101.4
Property, plant and equipment	200.0	200.3
Right-of-use assets	23.3	28.9
Intangible assets	171.1	156.9
Other receivables, deposits and prepayments	76.1	80.3
Deferred income tax assets	5.7	5.6
Total Non-Current Assets	476.2	472.0
Total Assets	2,862.8	3,573.4
Trade payables	129.7	91.7
Contract liabilities	5.6	4.9
Other payables and accruals	124.9	116.3
Short-term borrowings	29.7	0.0
Lease liabilities	7.6	15.1
Amounts due to related parties	4.1	17.0
Provision	7.9	0.0
Deferred income	3.7	3.7
Total Current Liabilities	313.2	248.7
Contract liabilities	0.0	0.8
Lease liabilities	20.1	16.0
Amounts due to related parties	5.0	34.8
Deferred income	18.1	21.9
Deferred income tax liabilities	13.3	14.1
Total Non-Current Liabilities	56.5	87.6
Total Liabilities	369.7	336.3
Total Equities	2,493.1	3,237.1



Cash Balance

- As at December 31, 2021, our total cash and cash equivalents were RMB 2,200.6mn.

* All numbers are rounded to one decimal place



Intention to Conduct On-market Share Repurchase

up to HK\$50,000,000 in value of the Shares

The board announced that it intends to exercise its authority under the general mandate (the “Repurchase Mandate”) to repurchase shares of the Company (the “Shares”) granted by the Shareholders at the annual general meeting of the Company held on 11 June 2021 (the “AGM”) to repurchase up to **HK\$50,000,000** in value of the Shares from the open market from time to time, subject to market conditions (the “Proposed Share Repurchase”).

Finance by its internal resources

The Company intends to finance the Proposed Share Repurchase **by its internal resources (other than proceeds from its global offering and listing of Shares).**

Up to 10% of the total No. of shares in issue on the date of AGM and the timeline

the Directors are authorised to repurchase up to 10% of the total number of Shares in issue on the date of the AGM, with such mandate to expire upon the earliest of: (a) the conclusion of the next annual general meeting of the Company; (b) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company (the “Articles”) or any applicable laws to be held; and (c) the date on which the authority given under the ordinary resolution approving the Repurchase Mandate is revoked or varied by an ordinary resolution of the Shareholders in general meeting. Under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”), the repurchase price of each Share shall be no more than 5% higher than the average closing market price for the Shares over the five (5) trading days immediately preceding each repurchase. Shares repurchased (if any) by the Company will be cancelled.

Company’s confidence in own business

The Board believes that a share repurchase in the present conditions will demonstrate the Company’s confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the Shareholders. The Board believes that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position. The Board considers that the Proposed Share Repurchase is in the best interest of the Company and its Shareholders as a whole.

Shareholders and potential investors should note that any purchase of Shares made by the Directors under the Proposed Share Repurchase will be subject to market conditions and will be at absolute discretion of the Directors. There is no assurance of the timing, quantity or price of any share repurchases or whether or not the Company will make any repurchases. Shareholders and potential investors should therefore exercise caution when dealing in the securities of the Company.



Q&A

GENOR
BIOPHARMA